Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:

NCT ID: NCT05742477 Not yet recruiting - Neonatal Sepsis Clinical Trials

Treatment Outcome With Antibiotic Use and Its Resistance Pattern Among Patient With Neonatal Sepsis

Start date: March 31, 2023
Phase:
Study type: Observational

Determine Treatment outcome with antibiotic use and its resistance pattern among neonatal sepsis patients

NCT ID: NCT05726500 Not yet recruiting - Emergencies Clinical Trials

Evaluation of Regional Ventilation Distribution in Patients Affected by Abdominal Sepsis After Emergent Laparotomy

CHESTOMY
Start date: February 15, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate regional ventilation distribution in patients admitted to the intensive care unit after emergent laparotomy due to abdominal sepsis. The main question it aims to answer is: • evaluate if patients admitted after an open abdomen strategy have a different regional ventilation distribution compared to patients in which abdomen is closed at the end of the procedure Participants will undergo non-invasive monitoring (esophageal pressure and electrical impedance tomography) and an blood gas analysis samples. Researchers will compare open abdomen group and closed abdomen group to see if the ventilation distribution pattern is different.

NCT ID: NCT05718804 Not yet recruiting - Sepsis Clinical Trials

Gut Microbiota and Sepsis-associated Acute Kidney Injury

GMASAKI
Start date: February 1, 2023
Phase:
Study type: Observational

Sepsis has emerged as one of the important life-threatening infectious diseases with high morbidity and mortality. Sepsis-associated kidney injury (SAKI) is one of the most common and serious complications of sepsis. It has been found that intestinal flora may affect the occurrence and development of a variety of diseases, and may also affect the pathogenesis of multiple SAKI, which is also regulated by host genetic factors. Therefore, the investigators speculate that gut microbiota composition may be associated with susceptibility to SAKI, and there are no studies reporting the association between gut microbiota and SAKI. The investigators intend to carry out a multicenter study in conjunction with the Department of Intensive Care of Qinghai Provincial People's Hospital. The structure and function of intestinal flora in septic patients with renal injury and septic patients less susceptible to renal injury are studied by 16S rDNA amplicon sequencing technology. The differences in composition, diversity and structural stability of intestinal flora between the two groups are analyzed to explore the genera that play a key role in the occurrence of the disease. By analyzing the differences between renal injury and inflammation levels in each group, the correlation between intestinal flora and SAKI, the possible influencing links involved, and the related factors affecting the prognosis of SAKI were revealed. The results of this study are helpful to further elucidate the pathogenesis of SAKI and provide new ideas and methods for the prevention and treatment of SAKI.

NCT ID: NCT05692128 Not yet recruiting - Neonatal Sepsis Clinical Trials

Frequency and Severity of Thrombocytopenia in Neonatal Sepsis

Start date: September 2023
Phase:
Study type: Observational

The aim of our study was to find the frequency of thrombocytopenia and its severity in neonates with sepsis

NCT ID: NCT05647096 Not yet recruiting - Sepsis Clinical Trials

Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating cfDNA/NETs in Subjects With Sepsis

NUC-CAP
Start date: August 1, 2024
Phase: N/A
Study type: Interventional

This is a prospective, multinational, multicentre, randomised, parallel-group, open-label study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of circulating cell-free DNA (cfDNA)/Neutrophil Extracellular Traps (NETs) in sepsis patients.

NCT ID: NCT05612893 Not yet recruiting - Sepsis Clinical Trials

Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study

DISPLAY
Start date: November 16, 2022
Phase:
Study type: Observational

The goal of this observational study is to describe the immune signature of acute pulmonary infection.The main questions it aims to answer are: 1. Nasal mucosal immune response in patients with influenza infection 2. Difference of immune response between Viral sepsis and Bacterial sepsis 3. Immunological differences between Viral sepsis and Viral pneumonia

NCT ID: NCT05606627 Not yet recruiting - Sepsis Clinical Trials

Correlation Between Antibiotic Resistance and Incidence of Sepsis in Community Acquired Pneumonia

Start date: December 2022
Phase:
Study type: Observational

Correlation between antibiotic resistance and incidence of sepsis in community acquired pneumonia in RICU patients.

NCT ID: NCT05585957 Not yet recruiting - NEONATAL SEPSIS Clinical Trials

THE VALUE OF INTERLEUKIN 6 AS A DIAGNOSTIC MARKER IN NEONATAL SEPSIS

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Neonatal sepsis is a leading cause of neonatal mortality and continues to be a formidable problem for neonatologists and pediatricians world over. The prevalence of neonatal sepsis varies in different countries; in developed countries it is 1 to 10 cases per 1000 live births and in developing countries the incidence of neonatal septicemia increases to 49 to 170 cases per 1000 live births. The normal fetus is sterile until shortly before birth as the placenta and amniotic sac are highly effective barriers to infections. At birth, the newborn loses the protection afforded to it in the uterus and gets exposed to the microbial world.Neonatal sepsis is broadly divided into two types according to age of onset: Early-onset sepsis (<72 Hrs) and late-onset sepsis (≥72 hrs-28 days). Early-onset sepsis is acquired during fetal life, delivery, or at the nursery.Bacterial organisms causing NS may differ among countries, however, in most developing countries, gram-negative bacteria remain the major source of infection.To date, blood culture is the gold standard test for diagnosing sepsis, but it has some inherent limitations. It takes at least three or five days to be decisive and can be mistakenly negative because antibiotics are initiated empirically before collection and a well-developed microbiology laboratory is required.CRP is one of the most widely studied and applied acute phase proteins clinically, which can be induced by pre-inflammatory factor interleukin-6 (IL-6) to synthesize by liver cells, and it starts to rise in 12-24 hours of inflammatory response and reaches its peak at 48 hours.Interleukin-6 (IL-6) is a pleiotropic cytokine expressed by different cells in response to infections.

NCT ID: NCT05540808 Not yet recruiting - Sepsis, Severe Clinical Trials

The Value of Full-targeted Pathogen Capture Metagenomics Next Generation Sequencing in Etiological Diagnosis of Sepsis

Start date: February 10, 2023
Phase:
Study type: Observational

The etiological diagnosis of sepsis is the key to guide clinical treatment. Metagenomic sequencing (mNGS) is very suitable for the diagnosis of sepsis due to its rapid, accurate and not easy to be disturbed by the environment. However, the conventional pathogen mNGS has potential risks such as low detection rate, loss of intracellular bacteria and fungi. At present, the latest fully targeted pathogen capture mNGS technology makes up for the shortcomings of conventional methods by bidirectional enrichment of pathogen nucleic acids. The aim of this study was to explore the value of fully targeted pathogen capture mNGS in improving etiological diagnosis in patients with sepsis compared with conventional methods.

NCT ID: NCT05524376 Not yet recruiting - Sepsis Clinical Trials

Regulatory Network and Diagnostic Value of Key Autophagy-related Genes in Sepsis

Start date: September 1, 2022
Phase:
Study type: Observational

Autophagy plays an important role in the occurrence and development of sepsis. This study aims to explore and verify the key autophagy-related genes in sepsis, then construct their regulatory networks and evaluate their potential diagnostic value, so as to provide new ideas for the diagnosis and treatment of sepsis.